<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220117053748N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-01</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The Effect of Capsaicin on Burning Moth</public_title>
      <acronym>VAS</acronym>
      <scientific_title>The Effect of Capsaicin Oral Solution in The Treatment of Burning Mouth in Patients Attending School of Dentistry and Affiliated Hospitals of Tehran Islamic Azad University of Medical Sciences</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>22</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61360</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation of participants in the study by the group statistician to random 4 blocks will be done using the Rand option of Excel software. Then, according to the number of samples, envelopes will be prepared in the package and given to the random person. Prior to treatment, the oral solution of capsaicin and placebo will be coded by someone outside the clinical research team. Therefore, both the patient and the evaluator will be blind, Blinding description: Prior to treatment, the oral solution of capsaicin and placebo will be coded by someone outside the clinical research team. Therefore, both the participants in the study and the outcome evaluator will be blind.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Condition 1: Burning mouth. Condition 2: Dry mouth.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Capsaicin oral solution using 10% extract of a mixture of coriander (Coriandrum sativum L.) and Hypericum perforatum (Hypericum perforatum L.) which was prepared by accelerated solvent method and 0.25% of Capsaicin in hydroalcoholic base with مiquid fructose solution and polyethylene glycol are formulated and standardized based on the presence of Capsaicin. This solution is diluted 20 drops of medicine or placebo in 20 cc of water three times a day for 30 days and gargle for at least 2 minutes. Intervention 2: Control group: This oral solution has been formulated using permitted pharmaceutical food dyes based on hydroalcoholic as well as liquid fructose solution and PEG, but without the use of coriander fruit extract, Hypericum perforatum and Capsaicin. This solution is diluted 20 drops of medicine or placebo in 20 cc of water three times a day and gargle for at least 2 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kimia Ghods</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, 9th Neystan Street, Pasdaran Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1931843511</zip>
        <telephone>+98 21 2269 2735</telephone>
        <email>kimiaghods2@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kimia Ghods</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 9, 9th Neystan Street, Pasdaran Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1931843511</zip>
        <telephone>+98 21 2269 2735</telephone>
        <email>kimiaghods2@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Absence of systemic disease
Existence of daily sensation of bilateral burning mouth continuously (4 to 6 months) and without obvious clinical symptoms
Improve the symptoms of burning mouth by eating food or drinking water
Non-interference of burning mouth with the patient's sleep</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Existence of any throat and nose lesions clinically
Existence of any local factor or systemic disease
Herbal or chemical drugs consumption
Existence of hypersensitivity reactions
Existence of physical or chemical agents
Existence of complete dentures, bad oral habits such asBruxism, oral mucosal diseases such as lichen planus, benign migratory glossitis, and bacterial, fungal, and viral infections.Neurological problems, endocrine disorders, anemia, gastrointestinal diseases, malnutrition, pregnancy and lactation, and pepper allergy
Existence of bad oral habits like Bruxism
Existence of oral mucosal diseases such as Lichen planus, benign migratory glossitis, and bacterial, fungal, and viral infections
Existence of neurological problems
Existence of endocrine disorders
Existence of anemia
Existence of gastrointestinal diseases
Existence of malnutrition
Pregnancy and lactation
Existence of pepper allergy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T28.0</hc_code>
      <hc_code>R68.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burn of mouth and pharynx</hc_keyword>
      <hc_keyword>Dry mouth, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Capsaicin oral solution using 10% extract of a mixture of coriander (Coriandrum sativum L.) and Hypericum perforatum (Hypericum perforatum L.) which was prepared by accelerated solvent method and 0.25% of Capsaicin in hydroalcoholic base with مiquid fructose solution and polyethylene glycol are formulated and standardized based on the presence of Capsaicin. This solution is diluted 20 drops of medicine or placebo in 20 cc of water three times a day for 30 days and gargle for at least 2 minutes.</i_keyword>
      <i_keyword>Control group: This oral solution has been formulated using permitted pharmaceutical food dyes based on hydroalcoholic as well as liquid fructose solution and PEG, but without the use of coriander fruit extract, Hypericum perforatum and Capsaicin. This solution is diluted 20 drops of medicine or placebo in 20 cc of water three times a day and gargle for at least 2 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Burning score in the standard burning mouth questionnaire. Timepoint: Filling in the mouth burning questionnaire at the beginning of the study (before the intervention) and on days 0 and 30 after starting the capsaicin solution. Method of measurement: Standard burning mouth questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Amount of Xerostomia. Timepoint: At the beginning of the study (before the intervention) and day 0, 30 after the start of capsaicin solution. Method of measurement: Standard dry mouth questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-10</approval_date>
        <contact_name>Research Ethics Committees of Islamic Azad University - Dental Branch Tehran - Iran</contact_name>
        <contact_address>No. 9, 9th Neystan Street, Pasdaran Street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
